Startup · $1.5m raised · Manufacturing
Developing a vaccine production platform for mosquito-borne viruses, beginning with Japanese encephalitis.
Every investor coverage indicates participated in a round Proboxis Biotechnology raised.
| Investor | Rounds | Invested |
|---|---|---|
| Biointelect Venturer | Accelerator | - |
Companies Proboxis Biotechnology acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Proboxis Biotechnology. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UQ spinout Proboxis Biotechnology has received $1.5 million via the first round of the Biointelect Venturer incubator to advance a vaccine platform against mosquito-borne diseases toward human clinical development.
An Australian infectious-disease incubator has selected six local biotechs to divide $10.48 million from its inaugural funding round, pairing non-dilutive cash with commercialisation support; the program is backed by an earlier MRFF grant.